Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? (Q30242015)

12 June 2017

1 reference

title

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? (English)

1 reference

12 June 2017

1 reference

1

Gianantonio Rosti

1 reference

12 June 2017

2

Fausto Castagnetti

1 reference

12 June 2017

3

Gabriele Gugliotta

1 reference

12 June 2017

4

Michele Baccarani

1 reference

12 June 2017

language of work or name

English

0 references

publication date

18 October 2016

1 reference

Nature Reviews Clinical Oncology

12 June 2017

published in

1 reference

12 June 2017

volume

14

1 reference

12 June 2017

issue

3

1 reference

12 June 2017

page(s)

141-154

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Severe peripheral arterial disease during nilotinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Pleural effusions due to dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Pulmonary arterial hypertension in patients treated by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Educational session: managing chronic myeloid leukemia as a chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

The concept of treatment-free remission in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Moving treatment-free remission into mainstream clinical practice in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Chronic myelogenous leukemia, version 1.2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Predictors of survival in thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

How I treat CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Management of chronic myeloid leukemia in blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Allogeneic transplantation for CML in the TKI era: striking the right balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.139

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27752053

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27752053

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27752053

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2016.139

1 reference

12 June 2017

1 reference